GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Institutional Ownership

Infant Bacterial Therapeutics AB (OSTO:IBT B) Institutional Ownership : 7.15% (As of May. 05, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Infant Bacterial Therapeutics AB's institutional ownership is 7.15%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Infant Bacterial Therapeutics AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Infant Bacterial Therapeutics AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Infant Bacterial Therapeutics AB Institutional Ownership Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Institutional Ownership Chart

Infant Bacterial Therapeutics AB Historical Data

The historical data trend for Infant Bacterial Therapeutics AB can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 10.95 11.03 10.51 6.73 6.73 6.93 7.36 7.25 7.15 7.15

Infant Bacterial Therapeutics AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Infant Bacterial Therapeutics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Institutional Ownership
Comparable Companies
XSAT:HAMLET B OSTO:DMYD B OSTO:MAGLE OSTO:FLUO OSTO:SYNACT OSTO:SANION OSTO:ONCO OSTO:CANTA OSTO:INIT OSTO:IRLAB A VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
9IB:Germany
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Website
https://www.ibtherapeutics.com
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines